TREATMENT OF HYPERLIPIDEMIA OF HIV+ SUBJECTS

这个子项目是众多研究子项目之一

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hyperlipidemia is a common metabolic abnormality in HIV+ patients on protease inhibitor combination therapy and this abnormality places these patients at increased risk for developing acute pancreatitis and also possibly for atherosclerosis. Fish oil, which contains high concentration of long-chain n-3 polyunsaturated fatty acids, has potent hypotriglyceridemic effect. Sitostanol, a plant sterol, has been shown to be a safe and efficacious way to reduce LDL cholesterol by 6-15% at doses of 2-3 grams per day. The aim of this study is to determine the efficacy and safety of fish oil and sitostanol, alone and in combination in treating the hyperlipidemia which occurs in HIV+ patients on protease inhibitor combination therapy.